Licensing & Partnerships

Partnership options

OptimDosing offers flexible partnership structures to meet your strategic needs. Whether you're looking to license IP, acquire technology, or explore joint development, we can structure a deal that works for both parties.

IP License

Field‑limited or geography‑limited licensing for incorporation into your products or studies. Ideal for companies looking to enhance existing platforms with patented dosing intelligence without full acquisition.

Includes: Patent rights, technical documentation, integration support, and ongoing updates.

Technology Transfer

Source code and know‑how transfer with onboarding and support. Complete technology package including algorithms, data models, and implementation guidance.

Includes: Full source code, technical architecture, training, and transition support.

Acquisition

Asset or entity acquisition to integrate OptimDosing's portfolio into your roadmap. Full ownership of IP, technology, and associated assets.

Includes: Complete IP portfolio, technology stack, documentation, and team knowledge transfer.

What we provide

IP Portfolio

  • Granted U.S. patents (US12009109B2, US12347538B2)
  • International applications (WO2021034677A1)
  • Patent claim summaries and freedom-to-operate analysis
  • Patent landscape documentation

Technology Assets

  • Technical architecture and system design
  • Source code and algorithms
  • Integration documentation and APIs
  • Prototype demo (symptom‑tracker module)

Support & Transition

  • Technical onboarding and training
  • Integration guidance and best practices
  • Ongoing support during transition
  • Knowledge transfer sessions

Why partner with OptimDosing?

🔒 Defensible IP

Granted patents protect core methods, not just implementations. Creates competitive moat and reduces risk of infringement claims.

📈 Market Timing

Polypharmacy is growing, regulatory tailwinds favor personalized dosing, and digital health adoption is accelerating. The market is ready.

✅ Validated Technology

Real-world deployment during COVID-19 validates core technology. Not just theoretical—proven in production environments.

One‑pagers (downloads)

Download our BD-ready summaries for specific use cases:

Start a conversation

All discussions are confidential and subject to mutual NDA.